Madrigal Pharmaceuticals, Inc.: stock overview

MDGLNASDAQHealthcare · Pharmaceutical Preparations

Price

$427.39

November 13, 2026Market cap $12.5B

DCF calculator

What Ploutos Investor adds for Madrigal Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2012
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Madrigal Pharmaceuticals had revenue of $1.4B over the last 12 months and a net loss of $155M. It holds more cash than debt, by $588M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$12.5B
29.25M shares
P/E
–
Revenue, 12 months
$1.4B
Net margin
-10.9%
2025: -30.1%, above 28% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

Fiscal years in figures

MDGL's revenue, profit, cash flow and dividend with each year-end price, from 2012 to 2022, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $6.8B
$12.5B
Enterprise value 
$11.9B
P/E 
–
EV / EBIT 
–
EV / Revenue 
8.3
P/B 3-year median: 11.4
19.9
FCF yield 3-year median: -6.7%
–
Earnings yield 3-year median: -7.1%
–

Profitability

Operating margin 
-10.7%
Net margin 
-10.9%
ROIC 
-13.0%
ROIC, 5-year average 
-60.8%
ROE 
-26.6%

Growth

Revenue, yearly change 
+432.1%
EPS, yearly change 
–
FCF, yearly change 
–

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$961M
Total debt 
$386M
Of which operating leases 
$13M
Net cash 
$588M
Net debt / EBITDA 
–
Interest cover 
-4.8x
Current ratio 
3.05

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+3.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

-31.3%

Above 29% of the 285 companies in its industry, and 11% of all.

Net margin

-30.1%

Above 28% of the 302 companies in its industry, and 10% of all.

ROE

-47.8%

Above 17% of the 267 companies in its industry, and 7% of all.

ROA

-22.9%

Above 23% of the 313 companies in its industry, and 8% of all.

Revenue growth

432.1%

Above 99% of the 292 companies in its industry, and 100% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
MADRIGAL PHARMACEUTICALS, INC.
CIK
1157601
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
29.25M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Madrigal Pharmaceuticals's filings show?

These are Madrigal Pharmaceuticals's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MDGL

Didn't find what you were looking for?

Ask us
What is MDGL's market cap?

Madrigal Pharmaceuticals, Inc.'s market cap is $12.5B, at a price of $427.39 on November 13, 2026 and 29.25M shares.

How much revenue does MDGL have?

Madrigal Pharmaceuticals had revenue of $1.4B over the last 12 months.

Does MDGL pay a dividend?

No. Madrigal Pharmaceuticals paid no regular dividend over the last 12 months.

Where do the figures come from?

From Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.